Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
Dear dkNET Community,
dkNET provides updates on activities of interest to the NIDDK-supported community. You could keep up to date on these activities through our Twitter feed @dkNET_info, through our Community Calendar, or through dkNET e-mail list. If you have an event or funding opportunities you'd like to advertise, please contact us info_at_dknet.org.
Events in January, 2019
Jan. 7, 2019
Abstract deadline: American Diabetes Association (ADA) 79th Scientific Sessions
More information: https://professional.diabetes.org/scientific-sessions
Jan. 11, 2019
Abstract submission deadline: ASBMB Deuel Conference
The Deuel Conference meets for two and one-half days annually at various West Coast locations and centers around an aspect of lipid metabolism. The Conference consists of five sessions and maintains an informal atmosphere, encourages free and open discussion, and is a forum for presentation of new and unpublished data. Attendees enjoy the informality and the Deuel conference provides the depth and breadth of expertise necessary for a high quality conference. Participation is by investigators in the field of lipids and lipoproteins from the around the world. Interested scientists are invited to register to attend the meeting and encourage trainees to submit abstracts.Location: Dana Point, CA, USA
More information: https://www.asbmb.org/deuelconference/
Jan. 13-17, 2018
Keystone Symposia: Host and the Environment in IBD: Scientific Advances Leading to New Therapeutics (A2)
The overall goal of this conference is to bring together world-class investigators and clinicians to discuss the latest scientific knowledge relevant to the pathogenesis of IBD and facilitate an interactive discussion to accelerate development of new opportunities to prevent and/or treat IBD. The specific aims of this conference are to: 1) Bring together a combination of clinical and basic investigators from both academia and industry to facilitate cross-disciplin
Location: Taos, NM, USA
More information: https://www.keystonesymposia.org/index.cfm?e=Web.Meeting.Summary&meetingid=1644&subTab=summary
Jan. 17-18, 2019
2nd PSL Chemical Biology Symposium
An international meeting in partnership with Institut Curie, Chimie ParisTech, ENS and ESPCI Paris; sponsored by Agilent Technologies and others. For the 2nd PSL Chemical Biology Symposium, the state of the art in chemical biology will again be presented by world leaders to feature the latest innovations and future trends in this innovative and dynamic field (bionconjugatioLocation: Paris, France
More information: https://pslchembiol.com
Jan. 27-31, 2019
Keystone Symposia: Signal Dynamics and Signal Integration in Development and Disease (J4)
Joint with the meeting on Cellular Plasticity: Reprogramming, Regeneration and Metaplasia (J3).
Location: Keystone, CO, USA
More information: http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1602
Jan. 30 - Feb. 3, 2019
Australian and New Zealand Society for Mass Spectrometry (ANZSMS)
The aim of the Society is to promote mass spectrometry by providing contact with local and international leaders in all areas, and providing a forum, through its meetings, for the presentation of research in mass spectrometry and related disciplines.Membership of the ANZSMS is open to any person with an interest in mass spectrometry. Members receive periodic information about topics such as future ANZSMS Conferences, visiting speakers, local group activities and funding support for postgraduate students and technical staff to attend mass spectrometry conferences.
Location: Auckland, New Zealand
More information: https://www.anzsms.org
Funding opportunities information and deadlines in January, 2019
Jan. 7, 2019
JDRF Funding Opportunity Application Due Date: Therapeutic Development and Early Clinical Testing of T Cell Targeted Immunotherapies for the Treatment of Type 1 Diabetes
Examples of pertinent topics include, but are not limited to: (1) IND-enabling studies of clinical candidates, including GLP/tox, studies if justified. (2) Pre-clinical mechanistic and/or efficacy studies of candidate therapeutics in appropriate animal models (effectiveness in two orthogonal models is desirable). (3) Optimization of lead candidate molecules. (4) Pilot clinical studies to demonstrate proof-of-mechan
More information: https://dknet.org/about/dknetnews/1142
Jan. 26, 2019
NIDDK Funding Opportunity Letter of Intent Due Date: Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) solicits applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through the controlled manipulation of beta cell replication, islet cell plasticity, and the reprogramming of pancreatic non-beta cells into beta-like cells, or through shielding the residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN).
More information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-014.html
Jan. 26, 2019
NIDDK Funding Opportunity Letter of Intent Due Date: Human Pancreas Analysis Program (HPAP) (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to continue the mission of the existing Human Pancreas Analysis Program (HPAP). This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology
More information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-015.html
Jan. 26, 2019
NIDDK Funding Opportunity Letter of Intent Due Date: Human Pancreas Analysis Program for Type-2 Diabetes (HPAP-T2D) (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to expand the operational scope of the existing Human Pancreas Analysis Program (HPAP) to the study of pancreata recovered from tissue donors with Type 2 Diabetes (T2D) and related metabolic disorders. This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology
More information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-18-016.html